Biogen's controversial Alzheimer’s drug generates $2 million sales in first few weeks after approval


Aduhelm by Biogen

Source: Biogen

Biogen‘s Alzheimer’s drug, Adhulem, generated $2 million in income in the first few weeks of its approval, the corporate mentioned Thursday in releasing its second-quarter earnings together with an open letter concerning the controversial drug.

Biogen hiked its income steerage for the 12 months, saying it expects complete sales of $10.65 billion to $10.85 billion this 12 months. That’s up from its earlier estimates of $10.45 billion to $10.75 billion. The new forecast assumes “modest” income from Adhulem in 2021, ramping up thereafter, the corporate mentioned.

Here’s how Biogen did in the course of the three months ended June 30 in contrast with what Wall Street anticipated, based on common estimates compiled by Refinitiv:

  • Adjusted EPS: $5.68 vs $4.54 anticipated
  • Revenue: $2.78 billion vs $2.61 billion anticipated

Shares of the corporate rose barely in early buying and selling.

Adhulem was authorised by the Food and Drug Administration on June 7. The drug, scientifically often known as aducanumab, affords new hope to buddies and households of sufferers residing with the illness and is anticipated to generate billions of {dollars} in income for the corporate.

Its approval has since been known as into query, nonetheless, and the pinnacle of the FDA is now calling for a federal investigation wanting into interactions between company workers and the biotech firm.

Biogen’s high analysis chief, Dr. Al Sandrock, defended the drug in an open letter launched alongside the corporate’s earnings Thursday, saying its approval has been topic to “extensive misinformation and misunderstanding.”

He mentioned it’s “normal” for scientists and clinicians to debate and debate knowledge from experiments and medical trials, however added these discussions have taken a flip “outside the boundaries of legitimate scientific deliberation.”

“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab,” Sandrock mentioned. “A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients.”

Leave a Reply

Your email address will not be published. Required fields are marked *